Alphatec (NASDAQ:ATEC) released its quarterly earnings data on Thursday. The medical technology company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.09), Morningstar.com reports. The business had revenue of $23.00 million during the quarter, compared to the consensus estimate of $23.92 million. Alphatec had a negative return on equity of 1,326.38% and a negative net margin of 3.32%.

Alphatec stock traded down $0.21 during midday trading on Friday, reaching $2.98. 157,185 shares of the stock traded hands, compared to its average volume of 82,652. Alphatec has a 12 month low of $2.31 and a 12 month high of $4.21. The firm has a market cap of $128.46 million, a PE ratio of -8.28 and a beta of 1.35. The company has a current ratio of 2.47, a quick ratio of 1.67 and a debt-to-equity ratio of 1.11.

ATEC has been the subject of a number of recent analyst reports. Zacks Investment Research lowered Alphatec from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 8th. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Alphatec in a research note on Friday, August 3rd.

Institutional investors have recently made changes to their positions in the stock. StepStone Group LP bought a new position in Alphatec during the second quarter valued at approximately $125,000. Renaissance Technologies LLC boosted its stake in Alphatec by 29.4% during the second quarter. Renaissance Technologies LLC now owns 484,645 shares of the medical technology company’s stock valued at $1,444,000 after buying an additional 110,058 shares during the last quarter. Stonepine Capital Management LLC bought a new position in Alphatec during the second quarter valued at approximately $2,692,000. Fondren Management LP boosted its stake in Alphatec by 74.3% during the second quarter. Fondren Management LP now owns 375,223 shares of the medical technology company’s stock valued at $1,118,000 after buying an additional 160,000 shares during the last quarter. Finally, Macquarie Group Ltd. bought a new position in Alphatec during the second quarter valued at approximately $116,000. 21.48% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Alphatec (ATEC) Posts Earnings Results, Misses Estimates By $0.09 EPS” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/11/10/alphatec-atec-posts-earnings-results-misses-estimates-by-0-09-eps.html.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.

See Also: What do I need to know about analyst ratings?

Earnings History for Alphatec (NASDAQ:ATEC)

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.